Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.010.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.13M | 3.59M | 3.38M | 3.64M | 3.67M |
| Gross Profit | -4.13M | -3.59M | -3.38M | -3.64M | -3.67M |
| SG&A Expenses | 4.23M | 3.86M | 3.67M | 3.74M | 3.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.36M | 7.45M | 7.05M | 7.39M | 7.49M |
| Operating Income | -8.36M | -7.45M | -7.05M | -7.39M | -7.49M |
| Income Before Tax | -7.95M | -7.09M | -6.77M | -7.15M | -7.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.95 | -7.09 | -6.77 | -7.15 | -7.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.95M | -7.09M | -6.77M | -7.15M | -7.42M |
| EBIT | -8.36M | -7.45M | -7.05M | -7.39M | -7.49M |
| EBITDA | -8.36M | -7.44M | -7.05M | -7.39M | -7.47M |
| EPS Basic | -2.73 | -3.83 | -7.00 | -10.82 | -15.06 |
| Normalized Basic EPS | -1.71 | -2.39 | -4.37 | -6.76 | -9.18 |
| EPS Diluted | -2.73 | -3.83 | -7.00 | -10.82 | -15.06 |
| Normalized Diluted EPS | -1.71 | -2.39 | -4.37 | -6.76 | -9.18 |
| Average Basic Shares Outstanding | 15.71M | 11.23M | 6.94M | 3.15M | 2.34M |
| Average Diluted Shares Outstanding | 15.71M | 11.23M | 6.94M | 3.15M | 2.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |